Welcome to our dedicated page for Parkervision SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for ParkerVision, Inc. (PRKR), a Florida corporation focused on radio-frequency (RF) technologies for advanced wireless communication systems. Through its periodic and current reports, ParkerVision provides detailed information on its operations, financial condition, litigation posture, and capital-raising activities.
Investors can use ParkerVision’s annual reports on Form 10-K and quarterly reports on Form 10-Q to review its RF technology and licensing focus, operating expenses, net losses, contingent payment obligations, and cash flows. These filings also include risk factor discussions that the company references in its press releases, covering topics such as outcomes of patent litigation, interpretations of patent law and claim scope, decisions by the Patent Trial and Appeal Board (PTAB), and market conditions affecting financing.
Current reports on Form 8-K are particularly important for tracking material events. Recent 8-K filings describe registered direct offerings of common stock under ParkerVision’s effective shelf registration statement on Form S-3, including sales to accredited investors and to a director. These filings outline subscription agreements, offering prices, aggregate purchase amounts, and legal opinions regarding the issuance of securities. Other 8-Ks furnish earnings press releases that summarize quarterly and year-to-date financial results and provide context for changes in operating expenses and contingent payment obligations.
Through this filings page, users can access ParkerVision’s real-time updates as they are filed with EDGAR, including 10-K, 10-Q, and 8-K reports, as well as registration statements and prospectus supplements related to its shelf registration. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections such as litigation disclosures, capital structure changes, and risk factors, and make it easier to interpret complex legal and financial language without replacing the full primary documents.
ParkerVision, Inc. files a prospectus supplement updating a resale registration that permits the resale of 9,387,500 shares of Common Stock. The registered shares consist of (i) 2,843,750 shares issued under purchase agreements, (ii) 6,343,750 shares issuable on conversion of convertible notes with a fixed conversion price of $0.16 per share, and (iii) 200,000 shares issuable upon exercise of options. The company states it will not receive proceeds from selling shareholders; however, it may receive up to $42,620 if the 200,000 Options are exercised for cash. The supplement also attaches a Form 8-K disclosing that the Compensation Committee extended the expiration dates of existing, fully vested nonqualified stock options for the CEO (2,660,000 options) and CFO (870,550 options) from August 7, 2026 to August 7, 2029, with no change to exercise price ($0.171) or share counts and an expected one-time non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. files a Prospectus Supplement registering 16,638,353 shares of Common Stock for resale by selling shareholders, consisting of shares issuable upon conversion of convertible promissory notes dated between May 10, 2022 and August 3, 2022 with a fixed conversion price of $0.13 per share. The supplement incorporates an attached Form 8-K dated April 22, 2026. The 8-K discloses that the Compensation Committee approved an extension of expiration dates for certain fully vested nonqualified stock options granted on August 7, 2019—2,660,000 options for CEO Jeffrey Parker and 870,550 options for CFO Cynthia French—moving the expiration from August 7, 2026 to August 7, 2029. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to that modification.
ParkerVision, Inc. is updating its resale prospectus to cover 1,578,946 shares of Common Stock available for resale by a selling stockholder, consisting of 1,052,631 shares and 526,315 shares issuable upon exercise of related warrants. The company will not receive proceeds from the resale; if the Warrants are exercised for cash, the company would receive up to $526,315. The supplement attaches a Form 8-K filed April 27, 2026 and also discloses that the Compensation Committee extended certain executive stock options' expiration dates to August 7, 2029, with an expected one-time non-cash share-based charge of approximately $360,000.
ParkerVision, Inc. files a Prospectus Supplement registering 13,342,953 shares of Common Stock for resale by selling stockholders under its shelf prospectus. The supplement states the company will receive no proceeds from resales; cash proceeds up to $2,833,756 are possible if outstanding warrants are exercised.
The filing also attaches a Form 8-K disclosing that the Compensation Committee extended expiration dates for previously issued, fully vested nonqualified stock options for CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029. The exercise price remains $0.171 per share. The company expects a one-time non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. files a Prospectus Supplement registering 5,871,584 shares of Common Stock for resale by selling stockholders. The supplement attaches a Form 8-K reporting that on April 22, 2026 the Compensation Committee extended the expiration dates of previously granted, fully vested nonqualified stock options held by CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029 with no change to exercise price ($0.171) or share counts. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to the modification. The resale proceeds will not be received by the company.
ParkerVision, Inc. registers 16,809,295 shares of Common Stock for resale under a prospectus supplement dated April 27, 2026.
The supplement states the 16,809,295 shares consist of convertible-note conversions, prior private placements, shares issued for services and payables, and warrants, and that the company will not receive proceeds from selling stockholders. The company may receive up to $3,900,000 if Aspire and Tailwinds warrants are exercised for cash; any proceeds are expected to be used for general working capital and corporate purposes.
Separately, the company disclosed a Compensation Committee action dated April 22, 2026 extending the expiration dates of outstanding options for the CEO (2,660,000 options) and CFO (870,550 options) from August 7, 2026 to August 7, 2029, which will result in an expected one-time non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. registers 18,014,164 shares of Common Stock for resale by selling stockholders under a prospectus supplement dated April 27, 2026.
The registration covers shares issuable upon conversion of convertible promissory notes across two tranches, shares issued for consulting services, and up to 1,800,000 shares issuable on a warrant with a $0.10 exercise price. The company will not receive proceeds from resales; if the Park Consulting Warrant is exercised for cash, the company would receive up to $180,000 to use for general working capital. The supplement attaches a Form 8-K reporting the Board Compensation Committee's approval to extend option expirations for two executives from August 7, 2026 to August 7, 2029, which will generate an estimated one-time, non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. files a Prospectus Supplement and attaches a Form 8-K to update its resale registration covering 17,189,660 shares of Common Stock. The supplement reconfirms resale registrations tied to prior private placements, a PIPE agreement with Aspire Capital, and convertible notes from 2018. The company will not receive proceeds from selling holders; issuer proceeds may occur only if certain warrants or PIPE-related instruments are exercised. The Form 8-K also discloses a Compensation Committee action to extend the expiration dates of previously awarded nonqualified stock options for CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029, with an unchanged exercise price of $0.171 per share. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to the modification.
ParkerVision, Inc. supplements its April 19, 2019 prospectus to register 12,800,000 shares of Common Stock for resale by selling stockholders, consisting of up to 7,800,000 shares issuable on conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from the resale; if the warrant is exercised for cash, the company would receive up to $800,000 to be used, if received, to fund patent enforcement actions and for general corporate purposes. The supplement also attaches a Form 8-K disclosing that the Compensation Committee approved an extension of the expiration dates of certain fully vested nonqualified stock options for the CEO and CFO from August 7, 2026 to August 7, 2029, which the company expects will result in a one-time non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. disclosed that its Compensation Committee approved changes to outstanding nonqualified stock options held by CEO Jeffrey Parker and CFO Cynthia French. The company extended the options’ expiration date from August 7, 2026 to August 7, 2029 to maintain their long-term incentive value.
The modified awards cover 2,660,000 options for Mr. Parker and 870,550 options for Ms. French, all originally granted on August 7, 2019 with an exercise price of $0.171 per share. These options were fully vested as of the modification date.
ParkerVision expects to record a one-time, non-cash share-based compensation charge of approximately $360,000 related to this modification. Only the expiration dates were changed; the exercise price, number of shares, vesting status, and all other terms remained the same, and no additional securities were issued.